Drug Profile
Umeclidinium/fluticasone furoate
Alternative Names: Fluticasone furoate/umeclidinium; GSK 685698/GSK 573719Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Androstadienes; Antiallergics; Antiasthmatics; Benzhydryl compounds; Bronchodilators; Glucocorticoids; Quinuclidines; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 28 Aug 2019 Discontinued - Phase-II for Asthma in Argentina, Russia, Thailand, Chile, USA (Inhalation)
- 02 Mar 2016 Umeclidinium/fluticasone furoate is in phase II development for Asthma COPD overlap syndrome
- 01 Apr 2012 Phase-II clinical trials in Asthma in USA, Argentina, Chile, Thailand and Russia (Inhalation)